Whittier Trust Co. increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 0.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,167 shares of the biopharmaceutical company’s stock after buying an additional 892 shares during the period. Whittier Trust Co.’s holdings in Celgene Corp. were worth $12,049,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in CELG. Analyst IMS Investment Management Services Ltd. raised its position in Celgene Corp. by 16.1% in the first quarter. Analyst IMS Investment Management Services Ltd. now owns 8,055 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 1,120 shares during the period. Dubuque Bank & Trust Co. raised its position in Celgene Corp. by 42.9% in the first quarter. Dubuque Bank & Trust Co. now owns 35,107 shares of the biopharmaceutical company’s stock valued at $3,514,000 after buying an additional 10,533 shares during the period. WASHINGTON TRUST Co raised its position in Celgene Corp. by 6.3% in the first quarter. WASHINGTON TRUST Co now owns 156,109 shares of the biopharmaceutical company’s stock valued at $15,624,000 after buying an additional 9,296 shares during the period. Pacad Investment Ltd. acquired a new position in Celgene Corp. during the first quarter valued at $3,113,000. Finally, Brick & Kyle Associates raised its position in Celgene Corp. by 21.3% in the first quarter. Brick & Kyle Associates now owns 10,645 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 1,870 shares during the period. Hedge funds and other institutional investors own 77.75% of the company’s stock.
Shares of Celgene Corp. (NASDAQ:CELG) traded up 0.04% during midday trading on Friday, hitting $104.07. 1,871,956 shares of the stock traded hands. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $128.39. The firm’s 50 day moving average price is $107.29 and its 200 day moving average price is $105.50. The company has a market capitalization of $80.67 billion, a PE ratio of 43.99 and a beta of 1.49.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.05. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The business earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. During the same period in the previous year, the firm earned $1.23 EPS. Celgene Corp.’s quarterly revenue was up 20.9% compared to the same quarter last year. Analysts expect that Celgene Corp. will post $5.71 EPS for the current year.
A number of research firms have commented on CELG. Zacks Investment Research raised shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $117.00 price objective for the company in a research note on Friday. Jefferies Group reaffirmed a “buy” rating and set a $134.00 price objective on shares of Celgene Corp. in a research note on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and set a $141.00 price objective on shares of Celgene Corp. in a research note on Monday, October 3rd. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $145.00 price objective on shares of Celgene Corp. in a research note on Sunday, October 2nd. Finally, Citigroup Inc. upped their price objective on shares of Celgene Corp. from $124.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, September 29th. Three research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $137.44.
In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total value of $1,033,532.40. Following the sale, the director now owns 72,142 shares in the company, valued at approximately $7,678,794.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael D. Casey sold 43,134 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $114.01, for a total value of $4,917,707.34. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.
Celgene Corp. Company Profile
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).
Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.